Author:
Lee Young Ho,Song Gwan Gyu
Publisher
Springer Science and Business Media LLC
Reference20 articles.
1. Ragab G, Elshahaly M, Bardin T (2017) Gout: an old disease in new perspective—a review. J Adv Res 8:495–511
2. Kim S‑K (2022) The mechanism of the NLRP3 Inflammasome activation and pathogenic implication in the pathogenesis of gout. J Rheum Dis 29:140–153
3. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P et al (2006) EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 65:1312–1324
4. Jia E, Yao X, Geng H, Zhong L, Xie J, Xiao Y et al (2022) The effect of initiation of urate-lowering treatment during a gout flare on the current episode: a meta-analysis of randomized controlled trials. Adv Rheumatol. https://doi.org/10.1186/s42358-022-00236-5
5. Taylor W, Schumacher H Jr, Singh J, Grainger R, Dalbeth N (2007) Assessment of outcome in clinical trials of gout—a review of current measures. Baillieres Clin Rheumatol 46:1751–1756